#1 Clinical Trials Search in Europe

Reparixin

Reparixin is an investigational drug being studied in clinical trials for various medical conditions. These trials aim to evaluate its safety and efficacy in treating diseases such as myelofibrosis, breast cancer, COVID-19 pneumonia, and complications related to organ transplantation. Researchers are exploring how Reparixin may help reduce inflammation, protect transplanted cells, and potentially improve outcomes for patients with these challenging conditions.

Table of Contents

What is Reparixin?

Reparixin is an experimental drug that is being studied for its potential to treat various medical conditions. It is also known by other names such as Repertaxin, REP, and DF 1681Y[1][2]. Reparixin belongs to a class of drugs called chemokine receptor antagonists. Specifically, it blocks the activity of a protein called CXCL8 (also known as interleukin-8 or IL-8) in the body[3].

How Reparixin Works

Reparixin works by inhibiting the activity of CXCL8, which is involved in inflammation and the recruitment of certain immune cells called neutrophils. By blocking CXCL8, Reparixin may help reduce inflammation and prevent damage to tissues in various medical conditions[3]. This mechanism of action makes Reparixin a potential treatment for conditions where inflammation plays a significant role.

Medical Conditions Treated with Reparixin

Reparixin is being studied for its potential to treat several medical conditions, including:

  • Type 1 Diabetes: Reparixin is being investigated for use in pancreatic islet transplantation, a procedure that can help people with type 1 diabetes produce insulin again[3][2].
  • Breast Cancer: Studies are exploring the use of Reparixin in combination with chemotherapy for treating metastatic breast cancer (cancer that has spread to other parts of the body)[1].
  • Myelofibrosis: This is a rare blood cancer that affects bone marrow function. Reparixin is being tested as a potential treatment for this condition[4].
  • COVID-19 and Other Pneumonias: Reparixin is being studied as a potential treatment for severe COVID-19 and other types of pneumonia[5][6].
  • Lung Transplantation: Researchers are investigating whether Reparixin can help prevent complications after lung transplant surgery[7].

Clinical Trials and Research

Reparixin is currently being studied in various clinical trials to determine its effectiveness and safety for different conditions. These trials involve different phases:

  • Phase 1 and 2 trials: These early-stage trials have shown that Reparixin appears to be generally safe and well-tolerated[1].
  • Phase 3 trials: Larger studies are ongoing to further evaluate the effectiveness of Reparixin for conditions like type 1 diabetes and COVID-19[2][6].

These clinical trials are helping researchers understand how well Reparixin works, what the optimal dosage might be, and what side effects it may cause.

How Reparixin is Administered

Depending on the condition being treated and the specific clinical trial, Reparixin may be administered in different ways:

  • Oral tablets: In some studies, Reparixin is given as oral tablets that patients take multiple times a day[4][6].
  • Intravenous (IV) infusion: For certain conditions, like during islet transplantation, Reparixin is given as a continuous IV infusion over several days[2].

The dosage and duration of treatment can vary depending on the specific condition and study protocol.

Potential Side Effects

As with any medication, Reparixin may cause side effects. However, it’s important to note that not everyone experiences side effects, and the full range of potential side effects is still being studied. In clinical trials, researchers carefully monitor participants for any adverse events (unwanted effects) that may occur during treatment[1].

Common side effects and their frequency are not yet well-established, as Reparixin is still in the investigational stage. Patients participating in clinical trials of Reparixin are closely monitored for any potential side effects or safety concerns.

Future Prospects for Reparixin

Reparixin shows promise in several areas of medicine, particularly where inflammation plays a significant role in disease progression. Ongoing research aims to:

  • Determine the most effective dosages for different conditions
  • Identify which patients are most likely to benefit from Reparixin treatment
  • Explore potential combinations with other treatments to enhance effectiveness
  • Evaluate long-term safety and efficacy

As research progresses, we may learn more about how Reparixin can be used to help patients with various inflammatory and immune-related conditions.

Condition Trial Phase Administration Key Outcomes Measured
Myelofibrosis Phase II Oral, 1200mg three times daily Efficacy per IWG/ELN criteria, bone marrow fibrosis grade, spleen volume
Metastatic Breast Cancer Phase Ib Oral, with paclitaxel Safety, pharmacokinetics, effects on cancer stem cells, tumor response
Severe COVID-19 Pneumonia Phase III Oral, 1200mg three times daily Mortality, need for mechanical ventilation, clinical improvement
Pancreatic Islet Transplantation Phase II/III Intravenous infusion Insulin independence, C-peptide levels, beta-cell function
Liver Transplantation Phase II Intravenous infusion Incidence of early allograft dysfunction, liver function parameters

FAQ

  • What is Reparixin and how does it work? Reparixin is an experimental drug that works by inhibiting the activity of CXCL8, a protein involved in inflammation. It is being studied for its potential to reduce inflammation and protect cells in various medical conditions.
  • What conditions is Reparixin being tested for in clinical trials? Reparixin is being studied in clinical trials for myelofibrosis, metastatic breast cancer, severe COVID-19 pneumonia, complications related to pancreatic islet transplantation, and liver transplantation.
  • How is Reparixin administered in these trials? Depending on the trial, Reparixin is administered either orally as tablets or intravenously as an infusion. The dosage and duration of treatment vary based on the specific study and condition being treated.
  • What are some potential benefits of Reparixin being investigated? Researchers are exploring whether Reparixin can improve outcomes in organ transplantation, reduce inflammation in severe COVID-19, enhance the effectiveness of cancer treatments, and help manage symptoms in myelofibrosis patients.
  • Are there any known side effects of Reparixin? As Reparixin is still being studied, its full side effect profile is not yet known. Clinical trials are monitoring patients closely for any adverse events to evaluate its safety alongside its potential benefits.

Ongoing Clinical Trials on Reparixin

  • Study on the Effectiveness and Safety of Reparixin for Adults with Acute Respiratory Distress Syndrome

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

Glossary

  • CXCL8: A protein involved in the inflammatory response that Reparixin is designed to inhibit.
  • Myelofibrosis: A rare blood cancer that affects bone marrow function and blood cell production.
  • HER-2 negative metastatic breast cancer: An advanced form of breast cancer that has spread beyond the breast and does not have high levels of the HER-2 protein.
  • Islet transplantation: A procedure where insulin-producing cells from a donor pancreas are transplanted into a person with type 1 diabetes.
  • ECMO: Extracorporeal membrane oxygenation, a life support technique used for patients with severe heart or lung failure.
  • Beta-cell function: The ability of pancreatic beta cells to produce and release insulin in response to blood glucose levels.
  • Hypoglycemia: Abnormally low blood sugar levels, which can be a complication of diabetes treatment.
  • C-peptide: A substance produced along with insulin that can be measured to assess insulin production by the pancreas.
  • Allograft: An organ or tissue transplanted from one individual to another of the same species.
  • Cancer stem cells (CSCs): A subpopulation of cancer cells believed to be responsible for tumor initiation, growth, and recurrence.

References

  1. https://clinicaltrials.gov/study/NCT02001974
  2. https://clinicaltrials.gov/study/NCT01967888
  3. https://clinicaltrials.gov/study/NCT01220856
  4. https://clinicaltrials.gov/study/NCT05835466
  5. https://clinicaltrials.gov/study/NCT05254990
  6. https://clinicaltrials.gov/study/NCT04878055
  7. https://clinicaltrials.gov/study/NCT00224406